FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish

Mithra has brushed off a missed co-primary endpoint in one of its two phase 3 clinical trials and given a bullish update on the menopause drug, which it expects to gain a global partner this year and go on to win approval on both sides of the Atlantic in 2024. Shares in the Belgian biotech rose 9% to around 22 euros ($25).